Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05483985 · ClinicalTrials.gov registry record · NA
Evaluation of the Alife Hera System as an Adjunctive Tool for the Prioritization of Embryos Deemed Suitable for Transfer
A NA study of Infertility, sponsored by Alife Health.
- Active
- Registry status
- NA
- Development phase
- 440
- Enrollment target
- 7
- Study locations
NCT05483985: Active NA study of Infertility, sponsored by Alife Health.
NCT05483985 is a NA study of Infertility that is active but no longer recruiting, run by Alife Health. The registered enrollment target is 440 participants, below the 7,584-participant average among 74 other Infertility trials with a reported enrollment target (94% lower). The trial reports 7 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05483985, a NA study of Infertility, is active but no longer recruiting, sponsored by Alife Health.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 440 participants
- Enrollment target
- 7
- Study locations
Study Summary
To evaluate the clinical pregnancy rate (pregnancy defined as fetal heartbeat at 6-8 weeks) with the adjunctive use of the Hera System (Hera System used with traditional morphological grading) with embryos already deemed suitable for transfer compared to trained embryologists using standard morphology criteria alone.
Primary Outcome
The primary study endpoint is clinical pregnancy - defined as a fetal heartbeat at 6-8 weeks.
Conditions Studied
Interventions
- DEVICE Hera Score
Study Locations (7)
California
- CCRM - Menlo Park
- Reproductive Science Center - San Ramon
Florida
- IVF Florida Reproductive Associates - Margate
- Center for Reproductive Medicine - Winter Park
Texas
- Ovation Fertility - Austin
- Aspire Fertility - San Antonio
Utah
- Reproductive Care Center - Sandy City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 440 participants |
| Start Date | 2022-06-13 |
| Est. Completion | 2025-01 |
| Phase | NA |
What the registry record for NCT05483985 still lists
NCT05483985 is an interventional study that assigns participants to a tested intervention. The registered 440 participants enrollment target is mid-sized for trials with a published cap, below the 7,584-participant average among 74 other Infertility trials with a reported enrollment target (94% lower).
The record links to 1 condition, with Infertility appearing as the primary indexed condition, and to 1 intervention - of which Hera Score is the first listed.
NCT05483985 lists 7 locations in 4 states (California, Florida, Texas).
Frequently Asked Questions
What is clinical trial NCT05483985 about?
NCT05483985 is a clinical study titled "Evaluation of the Alife Hera System as an Adjunctive Tool for the Prioritization of Embryos Deemed Suitable for Transfer". To evaluate the clinical pregnancy rate (pregnancy defined as fetal heartbeat at 6-8 weeks) with the adjunctive use of the Hera System (Hera System used with traditional morphological grading) with embryos already deemed suitable for transfer compared to trained embryologists using standard morpholo...
What is the current status of trial NCT05483985?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 440 participants. The study started on 2022-06-13. Estimated completion is 2025-01.
What conditions does trial NCT05483985 study?
This clinical trial studies the following conditions: Infertility.
What interventions are being tested in trial NCT05483985?
The interventions under investigation include: Hera Score (DEVICE).
Who is sponsoring clinical trial NCT05483985?
This trial is sponsored by Alife Health, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05483985 being conducted?
This trial has 7 study locations across California, Florida, Texas, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Infertility
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05483985's enrollment target sits among peer trials
440 27th of 74 higher than 48 of 74 other Infertility trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Infertility trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Gamete Treatment to Correct Fertilization Failure
RECRUITING · NA
-
Validating Incubators in the Lab: Optimizing Culture and Investigating blasTulation Yield
RECRUITING · NA
-
Use of Artificial Intelligence for Clinical Assessment of Assisted Reproductive Techniques and IVF Outcomes
RECRUITING · NA
-
Testicular Tissue Cryopreservation in Children
RECRUITING · NA
-
Sex Selection of Human Spermatozoa
RECRUITING · NA
-
Ovarian PRP Injections for Improved Embryo Quality Using Embryo Quality Score
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05114538 · 440 participants · NA
Improving the Part C Early Intervention Service Delivery System for Children with ASD
- NCT05117619 · 440 participants · NA
The HOME Program for Individuals With Traumatic Brain Injury and Family Members
- NCT05602194 · 440 participants · Phase 3
Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma
- NCT05624879 · 440 participants · NA
Accelerated Resolution Therapy for Early Maladaptive Grief
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI